According to Li et al., reports, combination therapy with oncolytic adenovirus targeting TGF-β signaling pathway and meso-specific CAR T cells, reveal a superior effect on inhibiting tumor growth [58]. This evidence concerns the gene TGFB1 and neoplasm.